Current Report Filing (8-k)
24 April 2018 - 11:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
April 24, 2018
AYTU
BIOSCIENCE, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
001-38247
|
|
47-0883144
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
|
|
|
|
373
Inverness Parkway, Suite 206, Englewood, Colorado
|
|
80112
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code:
(720) 437-6580
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
April 24, 2018, Aytu BioScience, Inc. (the “Company”) issued a letter to its shareholders to provide an update
on the Company’s progress in its continued launch of Natesto in the U.S. A copy of the letter is attached hereto
as Exhibit 99.1.
Item 9.01.
|
Financial Statements and
Exhibits.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
April 24, 2018
|
AYTU BIOSCIENCE, INC.
|
|
|
|
/s/
David Green
|
|
Name:
David Green
Title: Chief Financial
Officer
|
2
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From Apr 2024 to May 2024
AYTU BioPharma (NASDAQ:AYTU)
Historical Stock Chart
From May 2023 to May 2024